Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fentanyl Pectin Nasal Spray for Breakthrough Pain in Head/Neck Cancer
NCT01980498Phase 3Withdrawn
- Sponsor
- Molteni Farmaceutici
- Start
- Sep 2014
- Primary completion
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of fentanyl (transdermal patch + oral transmucosal lozenge) in breakthrough pain, sponsored by Molteni Farmaceutici. Planned start Sep 2014; status: withdrawn.
02
Drugs
fentanyl (transdermal patch + oral transmucosal lozenge)
03
Conditions
breakthrough pain
Beyond the preview
Go deeper on NCT01980498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01980498.